Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. [electronic resource]
Producer: 20140923Description: 111-24 p. digitalISSN:- 1941-837X
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bendamustine Hydrochloride
- Clinical Trials, Phase III as Topic
- Computer Simulation
- Cost-Benefit Analysis
- Cyclophosphamide -- administration & dosage
- Doxorubicin -- administration & dosage
- England
- Female
- Humans
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Nitrogen Mustard Compounds -- administration & dosage
- Prednisone -- administration & dosage
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Rituximab
- Vincristine -- administration & dosage
- Wales
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.